How to translate text using browser tools
1 October 2016 Challenges Towards Establishing Germline Gene Therapy for Inherited Mitochondrial Diseases
Naomi Shiga, Masahito Tachibana, Nobuo Yaegashi
Author Affiliations +

Mitochondrial DNA (mtDNA) mutation is associated with serious human disorders and affects multiple organs and tissues with high-energy requirements. Since the transmission of mtDNA is complex and is not fully understood, an accurate estimation of mtDNA disease transmission by preimplantation genetic diagnosis (PGD) or by prenatal diagnosis (PND) remains challenging. Recently, nuclear transfer techniques, including maternal spindle transfer (MST), pronuclear transfer (PNT) and polar body transfer (PBT), have shown the promising results. These methods avoid the transmission of mutated mtDNA from mother to offspring, and are collectively known as the mitochondrial replacement therapy (MRT). Further, the United Kingdom Parliament approved the Human Fertilisation and Embryology Authority (HFEA) to grant licenses for experimental use of MST and PNT in humans in 2015. Thus, a new era of assisted reproductive technology (ART), in which cures can be provided at the gamete or early zygote stages, is realistically approaching. In this review, we summarize the methods and the challenges confronting the clinical application of MRT.

©2016 Japan Society for Ova Research
Naomi Shiga, Masahito Tachibana, and Nobuo Yaegashi "Challenges Towards Establishing Germline Gene Therapy for Inherited Mitochondrial Diseases," Journal of Mammalian Ova Research 33(2), 89-99, (1 October 2016).
Received: 29 March 2016; Accepted: 1 May 2016; Published: 1 October 2016

This article is only available to subscribers.
It is not available for individual sale.

Maternal spindle transfer (MST)
Mitochondrial diseases
Mitochondrial replacement therapy (MRT)
Pronuclear transfer (PNT)
Get copyright permission
Back to Top